Safety evaluation and analysis of brigatinib in patients with lung cancer

Brigatinib is a targeted treatment drug for ALK positive non-small cell lung cancer (NSCLC). Its safety is a matter of great concern to both patients and doctors. Based on data from multiple clinical trials and practical applications, the overall safety profile of brigatinib in patients with lung cancer is good. With appropriate use and monitoring, most patients can tolerate treatment with brigatinib and derive significant benefit from it.

Although brigatinib is relatively safe, there are still some common side effects, such as respiratory tract infection, hypertension, anemia, cough, diarrhea, vomiting, etc. Most of these side effects are mild to moderate and can be controlled and alleviated with appropriate medical management. For example, for high blood pressure and anemia, doctors can adjust drug dosages or give corresponding treatments to reduce symptoms.

In addition to common side effects, brigatinib may also cause some more serious side effects, such as interstitial lung disease and arrhythmia. Therefore, during the use of brigatinib, doctors will closely monitor the patient's physical condition and conduct regular electrocardiogram and other examinations to ensure the patient's safety. At the same time, doctors will also adjust the treatment plan according to the patient's specific situation to reduce the risk of serious side effects.

For patients who require long-term use of brigatinib, its safety has also been fully verified. In clinical trials and practical applications, brigatinib has demonstrated good tolerability and long-term safety. Of course, the patient's physical condition still needs to be regularly monitored and evaluated during long-term use to ensure the effectiveness and safety of the drug.

References:

https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.9078